Millennium Management LLC Sells 19,242 Shares of Immutep Limited (NASDAQ:IMMP)

Millennium Management LLC cut its position in Immutep Limited (NASDAQ:IMMP) by 54.0% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 16,367 shares of the biotechnology company’s stock after selling 19,242 shares during the quarter. Millennium Management LLC’s holdings in Immutep were worth $36,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in the company. OLD Mission Capital LLC bought a new position in shares of Immutep in the fourth quarter worth about $36,000. Two Sigma Securities LLC acquired a new position in shares of Immutep in the fourth quarter worth approximately $74,000. Finally, ABC Arbitrage SA bought a new stake in shares of Immutep in the 4th quarter valued at $152,000. 2.32% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Separately, Wall Street Zen cut Immutep from a “hold” rating to a “sell” rating in a research note on Saturday.

Immutep Stock Performance

IMMP opened at $1.74 on Friday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 18.25 and a current ratio of 18.25. The company’s fifty day moving average price is $1.78 and its two-hundred day moving average price is $1.89. Immutep Limited has a 1-year low of $1.32 and a 1-year high of $2.80.

About Immutep

Immutep Limited, a clinical-stage biotechnology company, engages in developing novel LAG-3 Immunotherapy for cancer and autoimmune diseases. The company is involved in advancing therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), a cell surface molecule that plays a vital role in regulating the immune system.